CXCL10 and urinary bladder disorder: Chemokines are known contributors to symptoms of bladder disorders, and Perters found remarkably reduced levels of chemokines CXCL-1, CXCL-10, and CCL-2 in patients who had received sacral neuromodulation therapy for BPS/IC [24].